| Literature DB >> 25325732 |
Kwaku Kyeremeh1, Kojo Sekyi Acquah2, Mustafa Camas3, Jioji Tabudravu4, Wael Houssen5, Hai Deng6, Marcel Jaspars7.
Abstract
We report the structural characterization of a new pyrazinone analogue; butrepyrazinone, which was isolated from a new actinomycete strain Verrucosispora sp. K51G recovered from Ghanaian mangrove river sediment. Spectroscopy-guided fractionation led to the isolation of a compound from the fermentation culture and a combination of NMR spectroscopy, high-resolution mass spectrometry and computer-aided calculations revealed that butrepyrazinone (10) possesses an unusual methylation pattern on the pyrazinone ring. Butrepyrazinone (10), however, displayed no antibacterial activity against Gram-positive S. aureus ATCC 25923, the Gram-negative E. coli ATCC 25922 and a panel of clinical isolates of methicillin-resistant S. aureus (MRSA) strains, suggesting that 10 may act as a signal molecule for this strain. Although the same molecule has been synthesized previously, this is the first report to disclose the discovery of butrepyrazinone (10) from nature.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25325732 PMCID: PMC4210894 DOI: 10.3390/md12105197
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Substitution patterns in pyrazinone compounds isolated from microbes.
Figure 2Neighbor-joining tree based on nearly complete 16S rDNA gene sequences (1461 nt) showing relationships between isolate K51G and representatives of genera classified in the family Micromonosporaceae. Asterisks indicate branches of the tree that were also found using the maximum-likelihood and maximum-parsimony tree-making algorithms. The numbers at the nodes indicate levels of bootstrap support (%) based on a neighbor-joining analysis of 1000 re-sampled datasets; only values at or above 50% are given. T type strain, Bar 0.01 substitutions per nucleotide position.
1H and 13C NMR data of butrepyrazinone in CDCl3. δ in ppm, J in Hz.
| Position | δH Mult ( | δC Mult | HMBC |
|---|---|---|---|
| NH-1 | |||
| 2 | 157.5, C | 7 | |
| 3 | 154.6, C | 7, 12 | |
| N-4 | |||
| 5 | 132.2, C | 12, 13 | |
| 6 | 129.9, C | 13, 12 | |
| 7 | 4.10, s | 39.6, CH2 | 9, 9′ |
| 8 | 138.3, C | 7, 10, 10′ | |
| 9/9′ | 7.40, d (6) | 129.9, (CH)2 | 7, 10, 10′, 11 |
| 10/10′ | 7.25, t (6) | 128.8, (CH)2 | 9, 9′ |
| 11 | 7.18, t (6) | 126.9, CH | 9, 9′ |
| 12 | 2.21, s | 16.7, CH3 | |
| 13 | 2.28, s | 18.9, CH3 |
Figure 3Selected COSY data for butrepyrazinone.
Figure 4The best candidate structure calculated by the Structure Elucidator with 13C chemical shift deviations between experimental and predicted of the HOSE-code (dA) Incremental Method (dI) and Artificial Neural Net (dN).
Scheme 1Proposed biosynthetic pathway of butrepyrazinone from Verrucosispora sp. K51G. NRPS: Non-ribosomal peptide synthetase; A: Adenylation domain; T: Thiolation domain; C: Condensation domain; Re: NADH-dependent reduction domain.
Strains used in antibacterial screening of butrepyrazinone.
| Strain | Source of Isolate |
|---|---|
| ATCC | |
| ATCC | |
| SMRSA 105 | Toe wound |
| SMRSA 124 | Open wound |
| SMRSA 116 | Knee abscess |
| EMRSA 15 | Urine infection |
a Laboratory strains.